United States signals phased tariffs on imported generic drugs
Date of publication: August 3, 2026.
President Trump announced on social media on July 21, 2026, a proposed phased tariff approach for generic drugs imported into the United States. Under the announcement, imported generics would continue to face a
0% tariff from August 1, 2026, through July 31, 2028
. The rate would then increase to 100% for one year beginning August 1, 2028
, followed by a 200% tariff from August 1, 2029
.The stated objective is to encourage pharmaceutical manufacturers to establish U.S. production capacity. The announcement indicates that the planned measures are directed at generic drugs and that the existing treatment of patented, branded, and innovative medicines would remain unchanged.
For global trade professionals, the announcement is an early signal to assess exposure across finished generic products, active pharmaceutical ingredients, contract-manufacturing arrangements, and sourcing strategies. Key implementation details - including covered HTS classifications, country-of-origin treatment, potential exclusions, entry-date rules, and interaction with other U.S. tariff measures - have not been specified in the announcement.
Importers and manufacturers should begin mapping potentially affected supply chains, reviewing U.S. manufacturing and investment options, and monitoring for a formal presidential instrument and implementing guidance from U.S. agencies.
For information on how ONESOURCE Global Trade solutions can help with your trade compliance needs, contact your Account Manager or Customer Success Manager.